Spanish     Chinese

About Us

 

Toshio MIYATA  M.D., Ph.D.

 

"Drug discovery" pursued by pharmaceutical companies follows a stereotyped pattern and operates within a very narrow scope. For example, the same statin-type antihyperlipidemic and sartan-type antihypertensive drugs may be extensively developed and formulated by drug companies, whereas orphan drugs or drugs that target diseases which are overlooked by drug companies but are nonetheless of significant social impact (such as kidney diseases) are far from receiving the attention they deserve in new drug development.

Our unit focuses on  "academically driven drug discovery" via a cross-disciplinary approach involving inputs from biology, structural biology, pharmacology, chemistry, and computer engineering.

 

Our research platform employs an array of state-of-the-art technologies  including in silico hit discovery, lead optimization, pre-clinical trials, human clinical trials (microdose trials, early-phase exploratory clinical trials, POC trials) to complement rational drug discovery and development.

 

They should improve insights into human physiology/pharmacology and document the drug candidate's characteristics and therapeutic target relevant to disease. Such an approach should alter the balance of risks during the drug development dramatically, enable us to pursue many more promising compounds than is currently affordable, and develop them with a much greater probability of success.  

 

Researchers in academia is now able to contribute

to the drug discovery and development !



About | Privacy Policy | Sitemap
Copyright (C) 2010 Miyata lab. All Rights Reserved.